Journal Section:
Erratum

In the article “History of Adverse Pregnancy on Subsequent Maternal-Fetal Outcomes in Patients with Immunoglobulin A Nephropathy: A Retrospective Cohort Study from a Chinese Single Center” [Kidney Dis. 2022;8(2):160–7; DOI: 10.1159/000520586] by Lian et al., the following corrections to Table 1 should be observed.

Table 1.

Baseline clinical characteristics at the time of kidney biopsy

VariablesOverallWith adverse pregnancy historyWithout adverse pregnancy historyp value
N 100 54 46  
Age, yr 27.2 (4.0) 27.0 (3.5) 27.5 (4.5) 0.57 
Body mass index, kg/m2 20.1 (18.8, 22.1) 20.7 (19.5, 22.5) 19.5 (18.4, 21.2) <0.01 
Time from biopsy to pregnancy, yr 4.0 (2.0, 6.0) 4.0 (2.0, 7.0) 2.0 (1.0, 4.0) <0.01 
Time from biopsy to delivery, yr 3.0 (1.0, 5.0) 5.0 (3.0, 8.0) 3.0 (1.0, 5.0) <0.01 
Hypertension, n (%) 21 (21.0) 11 (20.4) 10 (21.7) 0.41 
Systolic BP, mm Hg 119.1 (18.3) 119.7 (18.0) 118.5 (18.9) 0.75 
Diastolic BP, mm Hg 77.0 (13.7) 77.0 (13.1) 77.0 (14.5) 0.99 
Mean arterial pressure, mm Hg 86.7 (80.0, 97.0) 86.7 (81.3, 97.0) 86.8 (79.7, 97.0) 0.54 
Proteinuria category, n (%), g/d    0.55 
 <1 65 (65.0) 35 (64.8) 30 (65.2)  
 1–2 27 (27.0) 16 (29.6) 11 (23.9)  
 >2 8 (8.0) 3 (5.6) 5 (10.9)  
Hemoglobin, g/L 121.0 (115.0, 128.0) 122.0 (115.0, 129.0) 121.0 (113.0, 127.0) 0.82 
Serum creatinine, mg/dL 0.7 (0.6, 0.9) 0.7 (0.7, 0.8) 0.8 (0.7, 0.9) 0.57 
eGFR, mL/min/1.73 m2 110.6 (90.7, 121.8) 112.3 (94.5, 121.0) 105.2 (87.0, 121.8) 0.47 
Serum albumin, g/dL 3.8 (3.6, 4.1) 3.9 (3.7, 4.1) 3.7 (3.5, 4.1) 0.08 
Oxford classification,an (%) 
 M1 88 (100.0) 47 (100.0) 41 (100.0)  
 E1 14 (15.9) 7 (14.9) 7 (17.1) 0.74 
 S1 47 (53.4) 22 (46.8) 25 (61.0) 0.08 
 T1/2 22 (25.0) 10 (21.3) 12 (29.3) 0.34 
 C1/2 28 (31.8) 15 (31.9) 13 (31.7) 0.82 
Treatment before pregnancy, n (%) 
 RAS blocker treatment alone 71 (71.0) 37 (68.5) 34 (73.9) 0.55 
 Glucocorticoids and/or immunosuppressive drugs 43 (43.0) 23 (42.6) 20 (43.5) 0.76 
VariablesOverallWith adverse pregnancy historyWithout adverse pregnancy historyp value
N 100 54 46  
Age, yr 27.2 (4.0) 27.0 (3.5) 27.5 (4.5) 0.57 
Body mass index, kg/m2 20.1 (18.8, 22.1) 20.7 (19.5, 22.5) 19.5 (18.4, 21.2) <0.01 
Time from biopsy to pregnancy, yr 4.0 (2.0, 6.0) 4.0 (2.0, 7.0) 2.0 (1.0, 4.0) <0.01 
Time from biopsy to delivery, yr 3.0 (1.0, 5.0) 5.0 (3.0, 8.0) 3.0 (1.0, 5.0) <0.01 
Hypertension, n (%) 21 (21.0) 11 (20.4) 10 (21.7) 0.41 
Systolic BP, mm Hg 119.1 (18.3) 119.7 (18.0) 118.5 (18.9) 0.75 
Diastolic BP, mm Hg 77.0 (13.7) 77.0 (13.1) 77.0 (14.5) 0.99 
Mean arterial pressure, mm Hg 86.7 (80.0, 97.0) 86.7 (81.3, 97.0) 86.8 (79.7, 97.0) 0.54 
Proteinuria category, n (%), g/d    0.55 
 <1 65 (65.0) 35 (64.8) 30 (65.2)  
 1–2 27 (27.0) 16 (29.6) 11 (23.9)  
 >2 8 (8.0) 3 (5.6) 5 (10.9)  
Hemoglobin, g/L 121.0 (115.0, 128.0) 122.0 (115.0, 129.0) 121.0 (113.0, 127.0) 0.82 
Serum creatinine, mg/dL 0.7 (0.6, 0.9) 0.7 (0.7, 0.8) 0.8 (0.7, 0.9) 0.57 
eGFR, mL/min/1.73 m2 110.6 (90.7, 121.8) 112.3 (94.5, 121.0) 105.2 (87.0, 121.8) 0.47 
Serum albumin, g/dL 3.8 (3.6, 4.1) 3.9 (3.7, 4.1) 3.7 (3.5, 4.1) 0.08 
Oxford classification,an (%) 
 M1 88 (100.0) 47 (100.0) 41 (100.0)  
 E1 14 (15.9) 7 (14.9) 7 (17.1) 0.74 
 S1 47 (53.4) 22 (46.8) 25 (61.0) 0.08 
 T1/2 22 (25.0) 10 (21.3) 12 (29.3) 0.34 
 C1/2 28 (31.8) 15 (31.9) 13 (31.7) 0.82 
Treatment before pregnancy, n (%) 
 RAS blocker treatment alone 71 (71.0) 37 (68.5) 34 (73.9) 0.55 
 Glucocorticoids and/or immunosuppressive drugs 43 (43.0) 23 (42.6) 20 (43.5) 0.76 

Data are expressed as mean and standard deviation and median and range. p < 0.05.

eGFR, estimated glomerular filtration rate; BP, blood pressure; RAS, renin-angiotensin system.

aAnalysis was based on 41 patients without adverse pregnancy history and 47 patients with adverse pregnancy history.

View Large

After publication of the article, the authors noted 2 errors in Table 1. Specifically, the entry “Proteinuria category >2” for the “With adverse pregnancy history” group was incorrectly listed as 5.66% and should be corrected to 5.6% (3/54). The overall of “C1/2” in the “Oxford classification” was incorrectly given as 29 (32.9) and should be corrected to 28 (31.8).

The corrected Table 1 is shown here.

© 2025 The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial